Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
2 reports, 2 independent
Updated Nov 12
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Canaccord Genuity Group added to the list of firms covering Kailera Therapeutics.1 source
Multiple investment banks initiated coverage and set ratings for Kailera Therapeutics.1 source
Keep exploring
The entities involved
-
TD Cowen
American investment bank
-
Leerink partners
U.S. investment bank
Nothing else this week.
Related events
- Leerink Partners began coverage on Shattuck Labs shares, and TD Cowen subsequently raised the shares to a strong-buy rating.
- Leerink Partners started coverage on ANI Pharmaceuticals shares.
- TD Cowen initiated coverage and set a buy rating for Interparfums.
- TD Cowen, Bank of America, and Royal Bank of Canada issued new ratings and coverage notes on November 5, 2026.
- Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.